Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther (2022) 13:551–567 https://doi.org/10.1007/s13300-022-01218-y
In the original article, the second heading in the results section was published incorrectly. The correct heading is “Effectiveness of semaglutide”.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Di Loreto, C., Minarelli, V., Nasini, G. et al. Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria. Diabetes Ther 13, 1251 (2022). https://doi.org/10.1007/s13300-022-01263-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-022-01263-7